Alex Bisberg

Learn More
Acute Myeloid Leukemia (AML) is a fatal hematological cancer. The genetic abnormalities underlying AML are extremely heterogeneous among patients, making prognosis and treatment selection very difficult. While clinical proteomics data has the potential to improve prognosis accuracy, thus far, the quantitative means to do so have yet to be developed. Here we(More)
Demo of Algorithms & Clinical Visualization In 2014, there will be 18,860 new cases of acute myeloid leukemia (AML), and 10,460 deaths from AML. There is urgency in finding better treatments for this type of leukemia, as only about a quarter of the patients diagnosed with AML survive beyond 5 years. The goal of the 2014 DREAM 9 Acute Myeloid Leukemia (AML)(More)
  • 1